Medivation
Industry | Pharmaceutical industry |
---|---|
Founded | 2004 |
Headquarters | San Francisco, California , United States |
Key people | David Hung & Steve Gorlin |
Owner | Pfizer |
Website | medivation.com |
Medivation was an American biopharmaceutical company focused on development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation was headquartered in San Francisco, California, beginning operations in December 2004 with the acquisition of Medivation Neurology, Inc.[1] Its final CEO was David Hung.[2]
Medivation, in collaboration with
Pfizer announced it would acquire the company in August 2016 for $14 billion and completed the acquisition in October 2016.[4]
Company history
Steve Gorlin[5] and David Hung founded Medivation in 2003. After watching a 28-year-old breast cancer patient die during his oncology fellowship David Hung said he must do something about it.[6]
2010 – Class action lawsuit
On March 3, 2010, Medivation's stock dropped $27.15 per share to close at $13.10, a 67% one-day decline on volume of 45 million shares.
The counsel for the case was Bernstein Liebhard and the
2016
In April, the company was linked with a number of potential acquirers including
Other suitors were Celgene and Genentech, which ultimately lost to Pfizer.[17]
In August, Pfizer announced that it would acquire the company for $14 billion[18] or $81.50 per share, a 21% premium over the closing price on August 19;[19] the acquisition was completed September 28, 2016.
Awards
Medivation CEO David Hung was the EY Entrepreneur of the Year 2014 National Winner.[20]
References
- ^ "Investor relations". Medivation. Archived from the original on 3 July 2007. Retrieved 17 November 2012.
- ^ "Management team". Medivation. Retrieved 17 November 2012.
- ^ "Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Medivation, Inc". Law Offices of Howard G. Smith. 2010-03-03. Archived from the original on 10 August 2014. Retrieved 17 November 2012.
- ^ "Pfizer Completes Acquisition of Medivation". Yahoo! Finance. Retrieved 4 January 2017.
- ^ "Nothing ventured, something gained?". www.bizjournals.com. Retrieved 23 October 2020.
- ISSN 0099-9660. Retrieved 2017-12-20.
- ^ a b "The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Medivation, Inc". New York: Bloomberg L.P. March 12, 2010. Archived from the original on 6 June 2022. Retrieved 17 November 2012.
- ^ Robbins Geller Rudman & Dowd (March 9, 2010). "Class action complaint for violation of the federal securities laws" (PDF). Northern District of California: Izard Nobel LLP. Archived from the original (PDF) on 3 March 2016. Retrieved 17 November 2012.
- ^ "Michael S. Bigin". Bernstein Liebhard LLP. Archived from the original on 24 April 2012. Retrieved 17 November 2012.
[Michael S. Bigin] represents investors in Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug's treatment of Alzheimer's disease.
- ^ "U. SETH OTTENSOSER". Bernstein Liebhard LLP. Archived from the original on 28 January 2013. Retrieved 17 November 2012.
[U. Seth Ottensoser] represents investors in Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug's treatment of Alzheimer's disease.
- ^ "Medivation, Inc". Securities class action clearinghouse. Stanford Law School. March 22, 2012. Archived from the original on 16 December 2013. Retrieved 17 November 2012.
- ^ Ninth Circuit. Court of Appeals
- ^ "Unpublished Dispositions (Memoranda)".
- ^ "Sanofi could go hostile with Medivation bid". 13 April 2016.
- ^ "AstraZeneca eyes Xtandi windfall with potential £7B bid for Medivation".
- ^ Joshua Jamerson and Noemie Bisserbe (29 April 2016). "Medivation Rejects Sanofi's $9.3 Billion Takeover Bid". WSJ.
- ^ "Medivation call for offers". Reuters. 29 July 2016.
- ^ "Pfizer to Acquire Medivation for $14B - GEN News Highlights - GEN". 22 August 2016.
- ^ "Pfizer to buy cancer drug firm Medivation for $14bn". BBC News. 22 August 2016.
- ^ Medivation. "Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner Medivation.com. Medivation, 17 December 2014.